Peptide Schedule
TesofensineSmall moleculeNo amino acid sequence. Icon reflects category theme only.Tesofensine Dosage Calculator
Tesofensine is a triple monoamine reuptake inhibitor originally developed for Alzheimer's and Parkinson's disease, where it was found to produce significant unintended weight loss in trial participants.
0.25mcg · Daily
Summary: Add 0mL BAC water to your 0.25mg vial. Draw to < 0.1 units on a U-100 syringe for a 0.25mcg dose. This vial will last 0 doses.
Cycle Planner
Tesofensine Pharmacokinetics
Pharmacokinetics — Active Dose Over Time
t½ = ~9 days (220 hours)Disclaimer: This curve is a simplified first-order exponential decay model. Actual pharmacokinetics vary based on injection site, individual metabolism, body composition, and other factors. Half-life values are approximate and based on available preclinical and clinical literature. Many research peptides lack formal human pharmacokinetic studies. This is for educational purposes only — not medical advice.
Tesofensine Dosing Protocol
| Level | Dose / Injection | Frequency |
|---|---|---|
| Beginner | 0.25mg | Daily |
| Moderate | 0.5mg | Daily |
| Aggressive | 1mg | Daily |
Note: Oral capsule — no reconstitution needed. Triple monoamine reuptake inhibitor (serotonin, norepinephrine, dopamine). Not FDA-approved. Phase 3 completed in Mexico. Take once daily in the morning. Active metabolite M1 has a ~16-day half-life, contributing to prolonged activity. Monitor heart rate during treatment.
About Tesofensine
Tesofensine is a triple monoamine reuptake inhibitor originally developed for Alzheimer's and Parkinson's disease, where it was found to produce significant unintended weight loss in trial participants. It works by blocking the reuptake of three key neurotransmitters — serotonin, norepinephrine, and dopamine — in the brain, increasing their availability at the synapse. This triple action distinguishes it from older weight loss drugs like sibutramine, which primarily targeted only two of the three monoamines. In Phase 2 clinical trials, tesofensine at 0.5 mg daily produced an average body weight reduction of 9.2% over 24 weeks when paired with a calorie-restricted diet, roughly double the effect seen with previously approved anti-obesity medications at the time. The 1.0 mg dose reached 10.6% weight loss. These results caught attention because tesofensine achieved GLP-1-class weight loss through an entirely different pathway — central nervous system appetite regulation rather than gut hormone signaling. Tesofensine suppresses appetite by increasing dopaminergic and noradrenergic tone in hypothalamic feeding circuits. Recent research shows it silences a subset of GABAergic neurons in the lateral hypothalamus, directly reducing the neural drive to eat. It may also modestly increase resting energy expenditure, adding a thermogenic component to its weight loss effect. The compound is taken as a once-daily oral capsule, which offers a practical advantage over injectable GLP-1 agonists. Its long half-life of approximately 9 days means steady-state plasma levels are reached after several weeks, and effects persist well beyond a single missed dose. Saniona's partner Medix completed a Phase 3 program confirming the weight loss and safety profile seen in earlier trials, and a regulatory submission in Mexico was filed in 2025. Tesofensine is not currently approved by the FDA or EMA.